In 1936 studies on 3 patients with purpura haemorrhagica following neoarsphenamine therapy were reported.1 We ascertained by experiments that 2 of these patients were very sensitive to neoarsphenamine but apparently not sensitive to mapharsen, as the intravenous injection of this arsphenamine derivative failed to produce any significant effects on the platelets and capillaries or any untoward constitutional reaction. The third patient of the series disappeared from observation after leaving the hospital; hence no experimental studies were made.
Since publication of the report mentioned, we have had an opportunity to study 6 additional patients who showed hemorrhagic phenomena following the therapeutic use of arsphenamine derivatives. It appeared to us important to record our experimental studies on these patients, particularly those on 5 patients of the series who showed typical purpura haemorrhagica following the use of neoarsphenamine or of bismarsen but who had no apparent reaction following the intravenous injection of
FALCONER EH, EPSTEIN NN. PURPURA HAEMORRHAGICA FOLLOWING NEOARSPHENAMINE AND BISMARSEN THERAPY: FURTHER STUDIES ON SENSITIVITY TO ARSPHENAMINE AND TOLERANCE TO MAPHARSEN. Arch Intern Med (Chic). 1940;65(6):1158–1177. doi:10.1001/archinte.1940.00190120075007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: